Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I2GP
|
|||
| Former ID |
DNC011206
|
|||
| Drug Name |
2-(2-cyclohexylidenehydrazinyl)-4-p-tolylthiazole
|
|||
| Synonyms |
CHEMBL1253700; 2-(2-cyclohexylidenehydrazinyl)-4-p-tolylthiazole; BDBM50326648; ZINC54362881; AKOS005139686; ST51067932
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H19N3S
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)C2=CSC(=N2)NN=C3CCCCC3
|
|||
| InChI |
1S/C16H19N3S/c1-12-7-9-13(10-8-12)15-11-20-16(17-15)19-18-14-5-3-2-4-6-14/h7-11H,2-6H2,1H3,(H,17,19)
|
|||
| InChIKey |
KHLVZVWWHKJADP-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Monoamine oxidase type B (MAO-B) | Target Info | Inhibitor | [1] |
| BioCyc | Superpathway of tryptophan utilization | |||
| Tryptophan degradation via tryptamine | ||||
| Dopamine degradation | ||||
| Putrescine degradation III | ||||
| Noradrenaline and adrenaline degradation | ||||
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Arginine and proline metabolism | ||||
| Histidine metabolism | ||||
| Tyrosine metabolism | ||||
| Phenylalanine metabolism | ||||
| Tryptophan metabolism | ||||
| Drug metabolism - cytochrome P450 | ||||
| Metabolic pathways | ||||
| Serotonergic synapse | ||||
| Dopaminergic synapse | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| 5-Hydroxytryptamine degredation | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| WikiPathways | Tryptophan metabolism | |||
| Dopamine metabolism | ||||
| Phase 1 - Functionalization of compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.